Novoheart Limited – Trademark Portfolio
Entity Type: 16
Novoheart Limited holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include MYHEART and NOVOHEART. The owner is based in Shatin, N.T..
Unit 229,2/F,No.12 Science Park West Ave
Hong Kong Science Park
Shatin, N.T. , HK
Showing of trademarks Trademarks
Trademark Classifications
Novoheart Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Novoheart Limited have?
Novoheart Limited has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 1 abandoned, 1 cancelled.
What trademark classes does Novoheart Limited file in?
Novoheart Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Novoheart Limited's most well-known trademarks?
Novoheart Limited's registered trademark portfolio includes well-known marks such as MYHEART and NOVOHEART. These are among 2 currently registered trademarks in the portfolio.
What is Novoheart Limited's trademark registration success rate?
Novoheart Limited has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.